Cancer Antigen-GI (CA 19-9)
0080461
 
Ordering Recommendation
 
Mnemonic
CA-GI
Methodology
Quantitative Electrochemiluminescent Immunoassay
Performed
Sun-Sat
Reported
Within 24 hours
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Serum separator tube or plasma separator tube. Also acceptable: Green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature
Frozen.
Unacceptable Conditions
Body Fluid (refer to Cancer Antigen-GI (CA19-9), Body Fluid, ARUP test code 0020746). Specimens collected in sodium citrate.
Remarks
 
Stability
After separation from cells: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 3 months
Reference Interval
0-37 U/mL
Interpretive Data
Thistest uses Roche CA 19-9 electrochemiluminescent immunoassay. Results obtained with different test methods or kits cannot be used interchangeably. CA 19-9 is useful in monitoring pancreatic, hepatobiliary, gastric, hepatocellular, and colorectal cancer. CA 19-9 value regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.  
Note
 
CPT Code(s)
86301
Components
Component Test Code*Component Chart Name
0080461Cancer Antigen-GI (CA 19-9)
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • CA 19-9 (Cancer Antigen-GI (CA 19-9))
  • CA-GI (Cancer Antigen-GI (CA 19-9))
  • Carbohydrate Antigen (Cancer Antigen-GI (CA 19-9))